Teicoplanin

Catalog No.S1399 Synonyms: Teichomycin

For research use only.

Teicoplanin (Teichomycin) is a glycopeptide antibiotic, used to treat serious infections caused by Gram-positive bacteria.

Teicoplanin Chemical Structure

CAS No. 61036-62-2

Selleck's Teicoplanin has been cited by 2 Publications

Purity & Quality Control

Choose Selective Bacterial Inhibitors

Biological Activity

Description Teicoplanin (Teichomycin) is a glycopeptide antibiotic, used to treat serious infections caused by Gram-positive bacteria.
In vitro

Teicoplanin is associated with small increases in the GI colonization by C. albicans. [1] The inhibitory action of Teicoplanin on proteoglycan polymerization but not on nucleic acid and protein synthesis indicates that the effect in the wall is due to the accumulation at this level of proteoglycan soluble precursors continuously produced by the cell. [2] Teicoplanin, at a concentration of 1 mg/mL, causes rapid lysis of exponential phase cells of Streptococcus faecalis. [3] Teicoplanin inhibits peptidoglycan synthesis in intact cells and in cell-free systems. Teicoplanin-induced lysis is dependent on the growth phase of B. pumilus at the time of addition of the antibiotic. Teicoplanin induces lysis after a longer lag phase with slowly growing Strep. jhecalis CCM 1875 and lysis is not very extensive. [4]

In vivo Teicoplanin therapy increases the survival rate whereas G-CSF therapy does not in comparison to other groups in neutropenic mice. Teicoplanin and G-CSF combination therapy improves survival rate when compared with groups II, III, IV. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Water 100 mg/mL
(58.5 mM)
DMSO Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 1709.39
Formula

C77H77N9O31Cl2·R

CAS No. 61036-62-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)OC1C(C(C(C(O1)CO)O)O)NC(=O)C)Cl)CO)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03909698 Recruiting Other: Blood and urine sampling Kidney Failure Chronic|Antibiotics|Hemodialysis University Hospital Ghent|University Ghent September 15 2016 --
NCT03229135 Completed Device: other antibacterial agents,breathing machine Pneumonia Gram-Positive Bacterial People''s Hospital of Zhengzhou University February 1 2015 --
NCT03177369 Completed -- Teicoplanin-based Antimicrobial Therapy|Staphylococcus Aureus|Bone and Joint Infection Hospices Civils de Lyon January 2015 --
NCT01324804 Unknown status -- Coronary Heart Disease|Surgical Wound Infection Medical University of Vienna November 2010 --
NCT00754273 Completed Other: etest susceptability testing Methicillin-resistant Staphylococcal Aureus Pneumonia University of Kentucky|Pfizer September 2008 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Teicoplanin | Teicoplanin ic50 | Teicoplanin price | Teicoplanin cost | Teicoplanin solubility dmso | Teicoplanin purchase | Teicoplanin manufacturer | Teicoplanin research buy | Teicoplanin order | Teicoplanin mouse | Teicoplanin chemical structure | Teicoplanin mw | Teicoplanin molecular weight | Teicoplanin datasheet | Teicoplanin supplier | Teicoplanin in vitro | Teicoplanin cell line | Teicoplanin concentration | Teicoplanin nmr